"Approvable" anticancer agent will be marketed by Rhone- Poulenc Rorer under agreement announced Dec. 8. Enzon will receive $6 mil. in licensing fees and 50% profit share. RPR will establish a specialty sales force dedicated to the PEG-L- asparaginase product. The two companies will also explore indications beyond the expected initial one of acute lymphoblastic leukemia in patients hypersensitive to native L-asparaginase.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth